Cardiorheumatology: Cardiac involvement in systemic rheumatic disease

Megha Prasad, Joerg Herrmann, Sherine E. Gabriel, Cornelia M. Weyand, Sharon Mulvagh, Rekha Mankad, Jae Kuen Oh, Eric Lawrence Matteson, Amir Lerman

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

Autoimmune rheumatic diseases can affect the cardiac vasculature, valves, myocardium, pericardium, and conduction system, leading to a plethora of cardiovascular manifestations that can remain clinically silent or lead to substantial cardiovascular morbidity and mortality. Although the high risk of cardiovascular pathology in patients with autoimmune inflammatory rheumatological diseases is not owing to atherosclerosis alone, this particular condition contributes substantially to cardiovascular morbidity and mortality - the degree of coronary atherosclerosis observed in patients with rheumatic diseases can be as accelerated, diffuse, and extensive as in patients with diabetes mellitus. The high risk of atherosclerosis is not solely attributable to traditional cardiovascular risk factors: dysfunctional immune responses, a hallmark of patients with rheumatic disorders, are thought to cause chronic tissue-destructive inflammation. Prompt recognition of cardiovascular abnormalities is needed for timely and appropriate management, and aggressive control of traditional risk factors remains imperative in patients with rheumatic diseases. Moreover, therapies directed towards inflammatory process are crucial to reduce cardiovascular disease morbidity and mortality. In this Review, we examine the multiple cardiovascular manifestations in patients with rheumatological disorders, their underlying pathophysiology, and available management strategies, with particular emphasis on the vascular aspects of the emerging field of 'cardiorheumatology'.

Original languageEnglish (US)
Pages (from-to)168-176
Number of pages9
JournalNature Reviews Cardiology
Volume12
Issue number3
DOIs
StatePublished - Mar 25 2015

Fingerprint

Rheumatic Diseases
Morbidity
Mortality
Atherosclerosis
Cardiovascular Abnormalities
Pericardium
Heart Valves
Autoimmune Diseases
Blood Vessels
Coronary Artery Disease
Myocardium
Diabetes Mellitus
Cardiovascular Diseases
Pathology
Inflammation

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Cardiorheumatology : Cardiac involvement in systemic rheumatic disease. / Prasad, Megha; Herrmann, Joerg; Gabriel, Sherine E.; Weyand, Cornelia M.; Mulvagh, Sharon; Mankad, Rekha; Oh, Jae Kuen; Matteson, Eric Lawrence; Lerman, Amir.

In: Nature Reviews Cardiology, Vol. 12, No. 3, 25.03.2015, p. 168-176.

Research output: Contribution to journalArticle

Prasad, Megha ; Herrmann, Joerg ; Gabriel, Sherine E. ; Weyand, Cornelia M. ; Mulvagh, Sharon ; Mankad, Rekha ; Oh, Jae Kuen ; Matteson, Eric Lawrence ; Lerman, Amir. / Cardiorheumatology : Cardiac involvement in systemic rheumatic disease. In: Nature Reviews Cardiology. 2015 ; Vol. 12, No. 3. pp. 168-176.
@article{9c7b636f27be43fb813bb0af23172541,
title = "Cardiorheumatology: Cardiac involvement in systemic rheumatic disease",
abstract = "Autoimmune rheumatic diseases can affect the cardiac vasculature, valves, myocardium, pericardium, and conduction system, leading to a plethora of cardiovascular manifestations that can remain clinically silent or lead to substantial cardiovascular morbidity and mortality. Although the high risk of cardiovascular pathology in patients with autoimmune inflammatory rheumatological diseases is not owing to atherosclerosis alone, this particular condition contributes substantially to cardiovascular morbidity and mortality - the degree of coronary atherosclerosis observed in patients with rheumatic diseases can be as accelerated, diffuse, and extensive as in patients with diabetes mellitus. The high risk of atherosclerosis is not solely attributable to traditional cardiovascular risk factors: dysfunctional immune responses, a hallmark of patients with rheumatic disorders, are thought to cause chronic tissue-destructive inflammation. Prompt recognition of cardiovascular abnormalities is needed for timely and appropriate management, and aggressive control of traditional risk factors remains imperative in patients with rheumatic diseases. Moreover, therapies directed towards inflammatory process are crucial to reduce cardiovascular disease morbidity and mortality. In this Review, we examine the multiple cardiovascular manifestations in patients with rheumatological disorders, their underlying pathophysiology, and available management strategies, with particular emphasis on the vascular aspects of the emerging field of 'cardiorheumatology'.",
author = "Megha Prasad and Joerg Herrmann and Gabriel, {Sherine E.} and Weyand, {Cornelia M.} and Sharon Mulvagh and Rekha Mankad and Oh, {Jae Kuen} and Matteson, {Eric Lawrence} and Amir Lerman",
year = "2015",
month = "3",
day = "25",
doi = "10.1038/nrcardio.2014.206",
language = "English (US)",
volume = "12",
pages = "168--176",
journal = "Nature Reviews Cardiology",
issn = "1759-5002",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Cardiorheumatology

T2 - Cardiac involvement in systemic rheumatic disease

AU - Prasad, Megha

AU - Herrmann, Joerg

AU - Gabriel, Sherine E.

AU - Weyand, Cornelia M.

AU - Mulvagh, Sharon

AU - Mankad, Rekha

AU - Oh, Jae Kuen

AU - Matteson, Eric Lawrence

AU - Lerman, Amir

PY - 2015/3/25

Y1 - 2015/3/25

N2 - Autoimmune rheumatic diseases can affect the cardiac vasculature, valves, myocardium, pericardium, and conduction system, leading to a plethora of cardiovascular manifestations that can remain clinically silent or lead to substantial cardiovascular morbidity and mortality. Although the high risk of cardiovascular pathology in patients with autoimmune inflammatory rheumatological diseases is not owing to atherosclerosis alone, this particular condition contributes substantially to cardiovascular morbidity and mortality - the degree of coronary atherosclerosis observed in patients with rheumatic diseases can be as accelerated, diffuse, and extensive as in patients with diabetes mellitus. The high risk of atherosclerosis is not solely attributable to traditional cardiovascular risk factors: dysfunctional immune responses, a hallmark of patients with rheumatic disorders, are thought to cause chronic tissue-destructive inflammation. Prompt recognition of cardiovascular abnormalities is needed for timely and appropriate management, and aggressive control of traditional risk factors remains imperative in patients with rheumatic diseases. Moreover, therapies directed towards inflammatory process are crucial to reduce cardiovascular disease morbidity and mortality. In this Review, we examine the multiple cardiovascular manifestations in patients with rheumatological disorders, their underlying pathophysiology, and available management strategies, with particular emphasis on the vascular aspects of the emerging field of 'cardiorheumatology'.

AB - Autoimmune rheumatic diseases can affect the cardiac vasculature, valves, myocardium, pericardium, and conduction system, leading to a plethora of cardiovascular manifestations that can remain clinically silent or lead to substantial cardiovascular morbidity and mortality. Although the high risk of cardiovascular pathology in patients with autoimmune inflammatory rheumatological diseases is not owing to atherosclerosis alone, this particular condition contributes substantially to cardiovascular morbidity and mortality - the degree of coronary atherosclerosis observed in patients with rheumatic diseases can be as accelerated, diffuse, and extensive as in patients with diabetes mellitus. The high risk of atherosclerosis is not solely attributable to traditional cardiovascular risk factors: dysfunctional immune responses, a hallmark of patients with rheumatic disorders, are thought to cause chronic tissue-destructive inflammation. Prompt recognition of cardiovascular abnormalities is needed for timely and appropriate management, and aggressive control of traditional risk factors remains imperative in patients with rheumatic diseases. Moreover, therapies directed towards inflammatory process are crucial to reduce cardiovascular disease morbidity and mortality. In this Review, we examine the multiple cardiovascular manifestations in patients with rheumatological disorders, their underlying pathophysiology, and available management strategies, with particular emphasis on the vascular aspects of the emerging field of 'cardiorheumatology'.

UR - http://www.scopus.com/inward/record.url?scp=84923582416&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923582416&partnerID=8YFLogxK

U2 - 10.1038/nrcardio.2014.206

DO - 10.1038/nrcardio.2014.206

M3 - Article

C2 - 25533796

AN - SCOPUS:84923582416

VL - 12

SP - 168

EP - 176

JO - Nature Reviews Cardiology

JF - Nature Reviews Cardiology

SN - 1759-5002

IS - 3

ER -